To the best of our knowledge, this is the first report of a high frequency of tumor-free animals (pathologically confirmed as cures) after treatment with tolerated combinations of a TTK inhibitor with paclitaxel, in a TNBC PDX model with limited response to either agent as a monotherapy. This evidence concerns the gene TTK and neoplasm.